FDA must regulate stem cell therapies to mitigate risks to patients and the public
Proceedings of the National Academy of Sciences · 17.03.2026 · 123 (11)
DOI: 10.1073/pnas.2508586123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 11.03.2026. Verfasst von Taylor Pike und 2 weiteren Autor:innen. Beteiligte Einrichtung: S. J. Quinney College of Law, University of Utah, Salt Lake City, UT 84112. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- S. J. Quinney College of Law, University of Utah, Salt Lake City, UT 84112.
- Boston College Law School, Newton Centre, MA 02459.
ORCID-Profile: Daniel G Aaron
Zitieren
APA
Pike, T., Chirba, M. A., & Aaron, D. G. (2026). FDA must regulate stem cell therapies to mitigate risks to patients and the public. Proceedings of the National Academy of Sciences, 123(11). https://doi.org/10.1073/pnas.2508586123
Vancouver
Pike T, Chirba MA, Aaron DG. FDA must regulate stem cell therapies to mitigate risks to patients and the public. Proceedings of the National Academy of Sciences. 2026;123(11). doi:10.1073/pnas.2508586123
BibTeX
@article{Pike2026,
author = {Pike, Taylor and Chirba, Mary Ann and Aaron, Daniel G},
title = {FDA must regulate stem cell therapies to mitigate risks to patients and the public},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {11},
doi = {10.1073/pnas.2508586123}
}
EUVIMED